Press "Enter" to skip to content

New patent expiration for Gilead drug EMTRIVA

0
Copyright © DrugPatentWatch. Originally published at New patent expiration for Gilead drug EMTRIVA

Annual Drug Patent Expirations for EMTRIVA
Annual Drug Patent Expirations for EMTRIVA

Emtriva is a drug marketed by Gilead and is included in two NDAs. It is available from two suppliers. There are two patents protecting this drug and one Paragraph IV challenge.

EMTRIVA drug price trends.

Drug patent litigation for EMTRIVA.

The generic ingredient in EMTRIVA is emtricitabine. Two suppliers are listed for this compound. Additional details are available on the emtricitabine profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at New patent expiration for Gilead drug EMTRIVA
    Get the DrugPatentWatch Daily Briefing

    ✓ Patent Expirations and Generic Entry

    ✓ Insightful Articles & Case Studies

    ✓ Patent Litigation & Challenges

    ✓ 505(b)(2) & Biosimilars

    ✓ Industry Trends

    DrugPatentWatch - Make Better Decisions